Drug intelligence / Profile preview

SBX-1967

Development stage: Preclinical
Lead developer: Stramsen Biotech

Overview

SBX-1967 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment of musculoskeletal conditions. It is specifically designed to alleviate bone and joint pain, treat bone and joint infections, and improve joint lubrication. The therapeutic is derived from Stramsen's proprietary database of over 8,000 medicinal plants and is part of a broader pipeline of botanical candidates. While specific molecular targets and clinical phase data have not been publicly disclosed, the company is pursuing a regulatory path toward FDA approval for the candidate as a botanical drug.

Beyond the preview

Go deeper on SBX-1967.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBX-1967.

Explore the full profile